> top > projects > ASCO_abstracts > docs
ASCO_abstracts  

Documents (3,155) JSON TSV

source DB source ID text size updated at # proj. # Ann. updated_at
asco@alo33 161478 Background: The optimal dose of accelerated hyperfractionated radiotherapy AHF-RT for limited-stage small-cell lung cancer L-SCLC remains unknon. The purpose of this study as to evaluate the eff 2.27 KB 2023-01-16 1 2023-01-16
asco@alo33 161479 Background: Contemporary therapies produce high cure rates in HL. Hoever, complications of treatment produce substantial morbidity and mortality. Identification of individuals at high risk for toxic 2.35 KB 2023-01-16 1 2023-01-16
asco@alo33 161480 Background: We previously reported that lo volume centers have higher inpatient mortality OR 3.26 than high-volume centers 3 inpatient chemotherapy CT month m hen delivering CT for patient 2.21 KB 2023-01-16 1 2023-01-16
asco@alo33 161487 Background: The mCRPC patient population is heterogeneous, and clinical outcomes are influenced by clinical presentation and treatment history. Using the Prostate Cancer Registry NCT02236637 datab 2.42 KB 2023-01-16 1 2023-01-16
asco@alo33 161494 Background: Most patients ith hepatocellular carcinoma HCC have underlying liver disease, therefore, precise preoperative evaluation of the patients liver function is essential. Methods: We develo 2.26 KB 2023-01-16 1 2023-01-16
asco@alo33 161496 Background: The use of single fraction SF radiotherapy in the treatment of PBM in the United States is no gaining clinical acceptance, especially at large institutional levels. In this cross-secti 1.98 KB 2023-01-16 1 2023-01-16
asco@alo33 161547 Background: Parotid gland malignancies are very rare and constitute less than 1 percent of all cancers. Fast neutrons are effective in controlling locally advanced salivary gland malignancies, thoug 2.06 KB 2023-01-16 1 2023-01-16
asco@alo33 161548 Background: Residual tumor detection in advanced stage ovarian cancer OC represents a critical challenge in the treatment of the disease. Optimal abdominal cytoreduction until no evidence of macro 2.21 KB 2023-01-16 1 2023-01-16
asco@alo33 161663 Background: TLS is considered an oncologic emergency and occurs hen large numbers of malignant cells die and release massive amounts of certain intracellular contents especially potassium and phospho 2.21 KB 2023-01-16 1 2023-01-16
asco@alo33 161681 Background: Hyperbilirubinaemia is a common disease effect in patients pts ith metastatic pancreatic cancer mPC . As clinical trials often exclude them, data on management of these pts are rare. 2.42 KB 2023-01-16 1 2023-01-16